Member Info for Jimzi

As a result of the repayment, the breach of certain performance triggers that arose as a direct result of COVID-19 has now been waived, NSF explained to investors this morning.

The UK-based consumer finance company secured the six-year £200m facility back in March to fund continued loan book growth for NSF’s branch-based and guarantor loans divisions.

This is provided by credit funds managed by Ares Management Corporation (NYSE: ARES).

Nick Teunon, NSF's CFO previously described the facility as “an important milestone” which would allow for the diversification of funding sources while signalling “a clear recognition of the quality and confidence in the Group's two largest and fastest-growing businesses."

In the UK, its 6 months unless fraudulent [which has no time limit]

Thats why the sp is volatile.
Some understand the business and others don't.

The massive drop is c19 and aperforth related.
It’s all down to the results now. If PFG type results are followed ( not saying they are) the whole reason’ d’etre for the fall is minimised to eliminated.

Finance Companies like this is like a bicycle - keep riding and the wheels go round and the performance/ divs/ cashflow keep going round
Fall off your bike ( c19) everyone sees whether you can get back on and continue .
Or is this a blip or a major inherent problem.
Imo it’s a blip

Jeez you must be keen to post that many characters (of nonsense btw)

Most peeps would just silently wait

continues to be a joke

500k is 4.6 v 5.812.
Its only £25k FFS

DMA's attempting to bore us to death - but volume right down - most are happy to wait.

Is it all over after round 1?

A dazed Maxwell reels after the judges deliver a sharp strike to the head.

Posted June 5, 2020, 4:00 AM
COURTS
U.S. District Court, District of Delaware
TOPICS
dismissalpatent infringement
Maxwell Techs. Inc.'s motion to dismiss, in CAP-XX Ltd.'s action against Maxwell for the infringement of two patents for a charge storage device, was denied by the federal district court in Delaware. The court found that (1) CAP-XX has pleaded facts plausibly establishing that specifically named Maxwell products meet the volumetric FOM limitations claimed in the patents, and (2) CAP-XX has alleged facts to plausibly establish that an accused Maxwell product meets the limitations of the exemplary claims of each asserted patent. Cap-XX, Ltd. v. Maxwell Techs., Inc., 2020 BL 206457, D. Del., 19-1733-CFC, 6/3/20

https://news.bloomberglaw.com/ip-law/search?query=cap-xx

He can't stamp on judges - who now have a precedent from the first case.

Canna is a discretionary fund - just in response to some holders wanting some cash out of the fund so the managers think, CPX had a good run recently, lets sell a few of them.- no different to Mr £6 commission selling yesterday.
If you can find me a share where no one sells - I'm in.

As IW summarises, its actually the best state CPX has ever been in - a pivotal period imo.

Well at least it has not been forward sold so not a bucket shop raise.!
When and how much do they need to actually start mining?

Quite right Sunny.
And check the RSP for 1.5m , the real story is revealed - not these auto trades - all a mirage

Correct - with the right patent lawyer and addressing prior art 100% - they can be completely watertight.
That's the point of the bloody things

Sold already.

Telsa wants the courts help when it suits them!!

https://www.reuters.com/article/us-ftc-qualcomm/automakers-urge-ftc-to-seek-appeal-after-defeat-in-qualcomm-case-idUSKBN25K29O

Has there been a broker note reflecting this change ?

Now now Mav.
I'm bullish but you can buy 50k at 69.5p

.the new cashed up, investment up company.
Let the newsflow being!

criticism I have of this placing is the absence of carrying values for ProAxis "not disclosed" and Sage-Tech - "confidential."
If Eddison can manage to rustle up a value for ProAxis in 2018 at £16m - why can the directors hazard a figure?
You need these figures to see how fair the placing price is - given it took 2 hours to fill the book and the 12 month lock in - it suggests it is a bargain.
That said, if EMV continue how they are doing and use their expertise to enhance the monetisation of NSCI assets as well, being able to buy at just over 0.5p above the placing price ain't bad to have an effectively new company.

Some HNW sold 1m the day before the placement announcement - no doubt bought in the placement.
Now these are the peeps you should get annoyed with - should be looked into by the FCA - lmao.

Oh Techie.
The real world has passed you by - your taking this bubble lark too literally!!

EMV business model and why it fits like a glove with NSCI.

They are a small cap corporate finance firm that gets all its costs paid and instead of taking large fees, they take an interest in a subsequent sale / listing - usually 20% net of investment cost.
For it to be effective you need a decent sized portfolio - they have - 8 and NSCI has 8.
You also need quality.
Take Sage - proprietary tech[meaning a monopoly] in a £1b a year [and growing] industry that's already done a deal with one NHS trust.
To scale up, it may need funds - but EMV is the organiser [not provider] of such funds - no risk.
Having the IPR will mean a healthy gross margin - a £1b annual market for the taking - won't happen overnight but a very lucrative opp imo.
]check out their website]
What intrigues me is that in the placement doc, its the one investment with terms are confidential next to it.

Plenty more of them as well.